Evidence for Site-Specific Absorption of a Novel ACE Inhibitor

@article{Grass1989EvidenceFS,
  title={Evidence for Site-Specific Absorption of a Novel ACE Inhibitor},
  author={George M. Grass and William T. Morehead},
  journal={Pharmaceutical Research},
  year={1989},
  volume={6},
  pages={759-765}
}
Moexipril {2-[(l-ethoxycarbonyl)-3-phenylpropyl]amino-l-oxopropyl]-6,7-dimethoxy-1,2,3,4-tetra-hydroisoquinoline-3-carboxylic acid (S,S,S)}, an ester prodrug of an ACE inhibitor, was formulated in controlled-release preparations with a range of in vitro release rates, to provide a prolonged input of drug in vivo. However, pharmacokinetic studies with the controlled-release dosage forms in humans produced plasma profiles with the same characteristics and time to peak as an immediate-release… CONTINUE READING